Cardiac toxicity is a well-known and potentially serious complication of hemato-oncology treatment. A preparative regimen (PR) followed by hematopoietic cell transplantation (HCT) represents a high risk for development of cardiotoxicity. 1, 2 Various methods including cardiac biomarkers have been recommended for monitoring cardiotoxicity. The applicability of cardiac troponins in this context has been extensively investigated, with inconsistent results. 3, 4 Recently, we applied new biomarkers of myocardial ischemia and necrosis-glycogen phosphorylase BB (GPBB) and heart-type fatty acid-binding protein (H-FABP)-in the assessment of cardiac toxicity associated with HCT and anthracycline chemotherapy in acute leukemia patients. 5, 6 Except for the acute leukemia setting, these new prospective biomarkers of cardiac injury (GPBB, H-FABP) have not been studied in patients treated for hematological malignancies.
The aim of our present study was to assess cardiac toxicity during PR and HCT for various hematological malignancies using multiple biomarkers of cardiac injurymyoglobin, creatine kinase MB (CK-MB mass), cardiac troponin I (cTnI), H-FABP and GPBB.
A total of 53 patients (mean age 49.9±12.3 years, median 54 years, 33 men) undergoing HCT for various hematological malignancies were studied. The diagnoses were as follows: acute myeloid leukemia 27, multiple myeloma 12, non-Hodgkin's lymphoma 5, Hodgkin's lymphoma 4, acute lymphoblastic leukemia/lymphoblastic lymphoma 3, chronic myeloid leukemia 1 and myelodysplastic syndrome 1. Thirty transplants were autologous, 23 allogeneic. The study was carried out with ethics committee approval. All patients gave a written consent before they were included in the study.
Cardiac biomarkers were measured using a Randox Evidence analyzer (Randox Laboratories Ltd., Crumlin, UK) the day after completion of PR (after PR) and the day after infusion of hematopoietic cell graft (after HCT). Values above the reference range on the basis of a number of cardiology studies and as recommended by the manufacturer were considered elevated. The cut-off values for cardiac injury were as follows: 76.0 mg/l for myoglobin, 4.80 mg/l for CK-MB mass, 0.40 mg/l for cTnI, 4.50 mg/l for H-FABP and 7.30 mg/l for GPBB. Echocardiographic evaluation of left ventricular (LV) function was performed in all patients by an experienced echocardiographer who was blinded to the cardiac biomarker data.
We found significant elevations in GPBB (47.30 mg/l) in 8 (15.1%) patients after PR and in 9 (17.0%) patients after HCT. H-FABP increased slightly above the cut-off after HCT in 1 (1.9%) patient. Other cardiac biomarkers (myoglobin, CK-MB mass, cTnI) remained within the reference range in all patients. No patient manifested clinical cardiotoxicity with symptoms of heart failure in the peritransplant period. We found a significant correlation between elevation in GPBB and diastolic LV dysfunction on echocardiography (defined as impaired relaxation; that is, E/A inversion and E wave deceleration time above 220 ms on the transmitral Doppler curve): r ¼ 0.603; Po0.0001.
Our results suggest that administration of PR followed by HCT for hematological malignancies could be associated with myocardial injury manifested by increased release of GPBB from cardiomyocytes, which could correlate with diastolic LV dysfunction on echocardiography. In asymptomatic patients, these findings could be considered to be a sign of acute subclinical cardiotoxicity. Whether these acute changes will have predictive value for development of treatment-related cardiomyopathy in the future is not clear and should be evaluated during a prospective follow-up. Further studies in a larger number of patients will be needed to confirm our preliminary results and define the potential role of new cardiac biomarkers in the assessment of cardiac toxicity in hemato-oncology.
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